期刊
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
卷 12, 期 12, 页码 1671-1680出版社
HARBORSIDE PRESS
DOI: 10.6004/jnccn.2014.0169
关键词
-
类别
These NCCN Guidelines Insights focus on some of the major updates to the 2014 NCCN Guidelines for Thyroid Carcinoma. Kinase inhibitor therapy may be used to treat thyroid carcinoma that is symptomatic and/ or progressive and not amenable to treatment with radioactive iodine. Sorafenib may be considered for select patients with metastatic differentiated thyroid carcinoma, whereas vandetanib or cabozantinib may be recommended for select patients with metastatic medullary thyroid carcinoma. Other kinase inhibitors may be considered for select patients with either type of thyroid carcinoma. A new section on Principles of Kinase Inhibitor Therapy in Advanced Thyroid Cancer was added to the NCCN Guidelines to assist with using these novel targeted agents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据